Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera
NCT05143957 · View on ClinicalTrials.gov ↗
Study Summary
The main purpose of this study is to evaluate the efficacy of sapablursen in reducing the frequency of phlebotomy and in improving quality of life assessments in participants with polycythemia vera.
Conditions Studied
Interventions
- DRUG sapablursen
Study Locations (13)
Other
- Border Medical Oncology Research Unit — Albury
- Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie, Klinika Hematoonkologii i Transplantacji Szpiku — Lublin
- Wojewódzki Szpital Specjalistyczny Sp. z o.o. — Słupsk
- MICS Centrum Medyczne Toruń — Torun
- University College London Hospitals NHS Foundation Trust — London
Alabama
- O'Neal Comprehensive Cancer Center University of Alabama at Birmingham — Birmingham
Arizona
- Mayo Clinic Hospital — Phoenix
New Jersey
- John Theurer Cancer Center — Hackensack
Ohio
- Cleveland Clinic Foundation — Cleveland
Texas
- University of Texas MD Anderson Cancer Center — Houston
New South Wales
- Calvary Mater Newcastle Hospital — Waratah
Quebec
- McGill University Health Centre — Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-12-30 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05143957
The ClinicalTrials.gov registry entry for NCT05143957 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 55 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Phlebotomy Dependent Polycythemia Vera appearing as the primary indexed condition, and to 1 intervention — of which sapablursen is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05143957 reports 13 study locations spanning 9 distinct geographic areas — top geographies include Other, Alabama, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05143957 about?
NCT05143957 is a clinical study titled "A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera". The main purpose of this study is to evaluate the efficacy of sapablursen in reducing the frequency of phlebotomy and in improving quality of life assessments in participants with polycythemia vera.
What is the current status of trial NCT05143957?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2021-12-30. Estimated completion is 2026-06.
What conditions does trial NCT05143957 study?
This clinical trial studies the following conditions: Phlebotomy Dependent Polycythemia Vera. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05143957?
The interventions under investigation include: sapablursen (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05143957?
This trial is sponsored by Ionis Pharmaceuticals, which has 55 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05143957 being conducted?
This trial has 13 study locations across Alabama, Arizona, New Jersey, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.